Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
By S. Rajkumar, S. Jacobus, N. Callander, R. Fonseca, D. Vesole, Michael E. Williams, R. Abonour, D. Siegel, M. Katz, P. Greipp. The Lancet Oncology, 2010
939 citations recorded by the source corpus.
Subfields: Hematology, Oncology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/20dfd2f3f5c82d6bff92bee11f745e202d6892db
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Continuous lenalidomide treatment for newly diagnosed multiple myeloma. (2012, neutral): “Neutropenia 100 (67) 52 (35) 97 (64) 49 (32) 45 (29) 12 (8)”
- Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. (2014, methodology): “Figure 1A shows the Kaplan-Meier (KM) curves of overall survival based on the data collected by November 2008.(10) The survival curve for the low-dose group (blue) is always above the one for the high-dose group (gold), except at the end of the follow-up.”
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, result): “The rate of thrombosis in the present study also appeared limited (6%), being lower than the 12% rate reported in the lenalidomide plus low-dose dexamethasone arm of an Eastern Cooperative Oncology Group phase III trial in the front-line setting.(17) This was attributable to the required use of aspi”